logo-loader
viewAdmedus Ltd

Admedus signs exclusive distribution agreement in Italy for its unique heart tissue product

According to the World Health Organisation, cardiovascular disease causes more than half of all deaths across Europe.

a human heart
Admedus' bio-scaffold is used to repair congenital heart deformities

Admedus Ltd (ASX:AHZ) has signed an exclusive distribution agreement with Medical Instruments S.p.A. to market and distribute its clinically-superior ADAPT® technology in Italy.

Medical Instruments was founded in 1972 and specialises in the fields of cardiac surgery, vascular surgery, interventional radiology and haemodynamics.

Under the agreement, Medical Instruments will initially distribute Admedus’ non-toxic and non-calcifying flagship ADAPT® bio-scaffold CardioCel®.

The bio-scaffold is used to repair congenital heart deformities and more complex heart defects. It is also used to reconstruct dysfunctional heart valves and valve leaflets.

 

Admedus chief operating officer David St Denis said: “Admedus is delighted to partner with Medical Instruments to distribute our unique, world-leading technology to the patients and surgeons of Italy who have already shown keen interest and adoption of our ADAPT® products.

“According to the World Health Organisation, cardiovascular disease causes more than half of all deaths across Europe, causing 46 times the number of deaths and 11 times the disease burden caused by AIDS, tuberculosis and malaria combined in Europe.”

 

 

St Denis added: “This creates an enormous need, and opportunity, for the type of innovative health solutions and technology that Admedus is focused on delivering.

“Through our partnership with Medical Instruments, who have more than 40 years of demonstrated experience and success in the Italian medical device industry, we anticipate solid growth and development in this key market.”

READ: Admedus progressing towards securing $18 million investment for immunotherapies division

The company is also making progress towards securing a $18 million investment for its immunotherapies business to support ongoing research and development, as well as operational activities.

Admedus recently signed a Memorandum of Understanding (MOU) with Hong Kong investor Star Bright Holding Ltd who has already paid a non-refundable break-fee of $500,000 to finalise the terms of the investment.

Quick facts: Admedus Ltd

Price: 0.0865 AUD

ASX:AHZ
Market: ASX
Market Cap: $51.11 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read